| Project/Area Number |
21591741
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | 公益財団法人がん研究会 (2011)
Japanese Foundation For Cancer Research (2009-2010) |
|---|
Principal Investigator |
MATSUSAKA Satoshi 公益財団法人がん研究会, がん化学療法センター臨床部, 研究員 (00372665)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | 大腸癌 / 化学療法薬 / バイオマーカー / 血管新生抑制剤 / bevacizumab / 末梢循環癌細胞(CTC) / 末梢循環血管内皮細胞(CEC) / 末梢循環血管内皮前駆細胞(CEP) / CEC / CXCR4 / CTC / 血管新生阻害剤 |
|---|
| Research Abstract |
This study investigated the prognosis of metastatic colorectal cancer treated with bevacizumab in combination with chemotherapy, focusing on circulating tumor cells, endothelial cells, and endothelial progenitors. We concluded the CEC status at the baseline and CEP on the day4 was correlated with the prognosis of patients treated with bevacizumab, suggesting that CEC, especially CXCR4-positive CEC, and CEP status may be useful in estimating prognosis.
|
